Considering the extreme heterogeneity of this tumor, we performed NGS analysis of a panel of genes in patients suffering from recurrent GBM, IDH-wildtype treated with regorafenib, to identify predictive factors for response to treatment. This evidence concerns the gene IDH1 and glioblastoma.